Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human VX-787 single and multiple ascending dose study in healthy volunteers
NL-OMON37724Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pimodivir in influenza (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability after single ascending doses, Safety and tolerability after multiple ascending doses and 2 more. Started Feb 2012; status: active, not recruiting.
02
Drugs
pimodivir
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON37724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37724.